To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.

 
 

Description

This scoping review aims to determine the extent and quality of evidence regarding prostate cancer progression outcomes in transgender women who have undergone hormone replacement therapy. Notably, transgender females undergoing hormone replacement therapy as a component of the gender affirmation treatment commonly have their prostate, rendering them vulnerable to developing prostate cancer. There is no current agreement about the likelihood of transgender women developing prostate cancer or the impact of hormone replacement therapy on oncogenic molecular pathways. Unfortunately, due to a lack of scientific data and inadequate trust and awareness in the medical community, transgender women are often not provided with the essential information needed to make informed decisions regarding their prostate health. This puts them at risk for a delayed diagnosis. Understanding PC development in transgender women is critical, and addressing this gap in scientific knowledge necessitates highlighting this issue.

Disciplines

Health and Physical Education | Health Services Research | Medical Education | Medical Sciences | Medicine and Health Sciences | Primary Care

Download

Share

COinS
 

Evidence of Prostate Cancer Progression in Transgender Women After Hormone Replacement Therapy - Scoping Review Protocol

This scoping review aims to determine the extent and quality of evidence regarding prostate cancer progression outcomes in transgender women who have undergone hormone replacement therapy. Notably, transgender females undergoing hormone replacement therapy as a component of the gender affirmation treatment commonly have their prostate, rendering them vulnerable to developing prostate cancer. There is no current agreement about the likelihood of transgender women developing prostate cancer or the impact of hormone replacement therapy on oncogenic molecular pathways. Unfortunately, due to a lack of scientific data and inadequate trust and awareness in the medical community, transgender women are often not provided with the essential information needed to make informed decisions regarding their prostate health. This puts them at risk for a delayed diagnosis. Understanding PC development in transgender women is critical, and addressing this gap in scientific knowledge necessitates highlighting this issue.